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Original Article
Purpose: We sought to evaluate the long-term outcomes for patients with exudative age-related macular degeneration (AMD) 
undergoing vitrectomy for breakthrough vitreous hemorrhage and to investigate possible prognostic factors.
Methods: Consecutive patients treated at two high-volume referral-based tertiary hospitals between July 2006 and Decem-
ber 2019 were retrospectively reviewed. Surgery was performed using the standard three-port vitrectomy. The primary out-
come was the change in best-corrected visual acuity (BCVA) over long-term follow-up, while secondary outcomes included 
the assessment of possible prognostic factors.
Results: Among 50 eyes from 50 patients included in this study, 23 (46%) were diagnosed with polypoidal choroidal vascu-
lopathy (PCV) and 27 (54%) were diagnosed with neovascular AMD. Preoperative vision at the time of vitreous hemorrhage 
onset was 20 / 3,027 (logarithm of the minimum angle of resolution [logMAR], 2.18 ± 0.34). At 12 months after surgery, the 
mean BCVA improved to 20 / 873 (logMAR, 1.64 ± 0.76; p < 0.001). At 24 months, the BCVA was 20 / 853 (logMAR, 1.63 ± 
0.75; p < 0.001). Univariate analysis revealed that older age (odds ratio [OR], 0.879; p = 0.007] and the presence of submac-
ular hemorrhage (OR, 0.081; p = 0.022) were factors associated with a poor 2-year visual outcome. Multivariable regression 
showed that older age (OR, 0.876; p = 0.026) and neovascular AMD (as compared with PCV) (OR, 0.137; p = 0.014) were 
significant negative factors influencing the 2-year visual outcome. The mean injection interval prior to vitrectomy was 4.53 
months, which extended to 27.64 months after vitrectomy (p = 0.028).
Conclusions: Younger age, the absence of submacular hemorrhage, and PCV type were associated with a favorable 2-year 
visual outcome after vitrectomy for vitreous hemorrhage in patients with exudative AMD. Overall, vitrectomy resulted in im-
proved visual acuity and patients showed a decreased need for anti-vascular endothelial growth factor therapy thereafter.
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Age-related macular degeneration (AMD) leads to se-
vere vision loss and legal blindness, with a prevalence rate 
of up to 8.7% worldwide, and is especially common in de-
veloped countries [1,2]. If not treated appropriately, exuda-
tive AMD (eAMD) may lead to massive submacular hem-
orrhages, breakthrough vitreous hemorrhage, disciform 
scarring, and uncommonly to severe serous retinal detach-
ment, which are all detrimental to long-term vision quality. 
Vitreous hemorrhage is a rare complication of eAMD, oc-
curring reportedly at a rate of 2% to 7%, but has a very 
critical impact on the visual prognosis [3]. Previous studies 
on surgical outcomes and prognostic factors for vitreous 
hemorrhage associated with eAMD have reported conflict-
ing results. Some studies have suggested that severe in-
flammatory reactions in the postoperative period after vit-
rectomy may explain the poor visual outcomes, with 
aggravation of the underlying inflammatory process inher-
ent in eAMD. Others have reported that surgical interven-
tion appears to result in favorable visual outcomes but did 
not discuss any prognostic factors [4-6].
Our understanding is further complicated by the mix of 
eAMD with polypoidal choroidal vasculopathy (PCV) in 
past studies, as PCV may be a pachychoroid-driven disor-
der different from that of typical neovascular AMD. Al-
though a few recent reports have focused solely on the re-
sults of treatment for PCV with breakthrough vitreous 
hemorrhage and evaluated possible predictive factors, no 
comparative analysis with long-term outcomes have been 
performed [7,8]. Thus, the current literature is sparse re-
garding the long-term (over 2 years) visual and surgical 
outcomes of eAMD with vitreous hemorrhage and prog-
nostic factors that may aid clinicians in guiding patients’ 
expectations. There are also conflicting views pertaining 
to the safety of performing combined cataract surgery 
with vitrectomy for eAMD with vitreous hemorrhage due 
to the possible aggravation of inflammation.
In this study, we investigated and compared the long-term 
visual and surgical outcomes for patients with either neo-
vascular AMD or PCV undergoing vitrectomy for break-
through vitreous hemorrhage. We further evaluated possible 
prognostic factors influencing long-term outcomes and as-
sessed the safety of combining cataract surgery with vitrec-
tomy.
Materials and Methods
This was a retrospective case series of consecutive pa-
tients diagnosed with vitreous hemorrhage associated with 
either neovascular AMD or PCV undergoing vitrectomy 
from July 2006 to December 2019 at two high-volume, re-
ferral-based tertiary hospitals, Severance Eye Hospital and 
Gangnam Severance Hospital, affiliated with Yonsei Uni-
versity College of Medicine. Institutional review board/
ethics committee approval was obtained from Gangnam 
Severance Hospital (3-2019-0378) and the study adhered to 
the tenets of the Declaration of Helsinki. Patient consent 
was waived after institutional review board review as this 
study was conducted retrospectively with no identifying 
features of individual patients.
Multimodal imaging was conducted to determine the 
underlying cause for vitreous hemorrhage, including ul-
tra-widefield fundus photography, optical coherence to-
mography (OCT), f luorescein angiography, and indocy-
anine green angiography with a confocal laser-scanning 
system (HRA-2; Heidelberg Engineering, Heidelberg, Ger-
many). PCV was diagnosed if indocyanine green angiog-
raphy showed polypoidal structures along with branching 
vascular networks or OCT revealed typical features. Pa-
tients not showing features of PCV and displaying findings 
of type 1 and 2 choroidal neovascularization or retinal an-
giomatous proliferation (type 3 choroidal neovasculariza-
tion) were all included as cases of neovascular AMD. Mas-
sive submacular hemorrhage was defined as hemorrhage 
greater than 4-disc diameters in the greatest linear length, 
with the determination made by two graders (TYK and 
HGK); when these graders disagreed, a final determination 
was made by the supervising grader (CSL).
Patients who were followed up with for a minimum of 
12 months after surgery were selected to undergo the anal-
ysis of the long-term outcomes. Patients with eyes with 
vitreous hemorrhage due to proliferative diabetic retinopa-
thy or retinal vein occlusion and those having other oph-
thalmologic diseases such as macular hole, choroidal mela-
noma, and rhegmatogenous retinal detachment were 
excluded from this research.
Surgery was performed by experienced retinal special-
ists (HJK, JHL, MK, CSL, SHB, and SSK). The standard 
three-port vitrectomy with either the 23- or 25-gauge sys-
tem was used according to each surgeon’s preference. Ad-
juvant surgical techniques such as combined cataract sur-
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gery, intravitreal anti-vascular endothelial growth factor 
(VEGF), intravitreal tissue plasminogen activator (tPA), 
gas (SF6 or C3F8)/silicone oil tamponade or drainage of 
submacular hemorrhage were performed at the discretion 
of the attending surgeon. Changes in preoperative and 
postoperative anti-VEGF injection frequency and numbers 
were assessed together with the mean duration interval be-
tween injections. Patients who received continuous an-
ti-VEGF injections with at least four injections prior to 
surgery were included for subgroup analysis. We defined 
the injection interval as the average injection time between 
two consecutive intravitreal anti-VEGF injections.
Visual acuity (VA) was measured by Snellen chart and 
converted to logarithm of the minimum angle of resolution 
(logMAR); furthermore, counting fingers was graded as 
20 / 2,000 (logMAR 2.0), hand motion was graded as 20 / 
3,990 (logMAR 2.3), light perception was graded as log-
MAR 2.6, and no light perception was graded as logMAR 
2.90. Vision was recorded for up to 2 years of follow-up to 
analyze the visual change throughout the treatment dura-
tion. To analyze prognostic factors, vision better than 
counting fingers was defined as “favorable VA” [9,10]. We 
defined VA at the time of vitreous hemorrhage as preoper-
ative VA, while initial VA was recorded when patients first 
visited the clinic.
Finally, we analyzed changes in OCT features including 
Table 1. Baseline characteristics (n = 50)
Characteristics Value






Pseudophakic eyes 4 (8.0)
Presence of submacular hemorrhage 39 (78.0)
Visual acuity (logMAR, Snellen equivalent)
At the time of vitreous hemorrhage 2.18 ± 0.34 (20 / 3,027)*
Last follow-up 1.67 ± 0.76 (20 / 935)
Wet AMD type
PCV 23 (46.0)
Neovascular AMD (types 1 and 2) 26 (52.0)
RAP (type 3) 1 (2.0)
Mean postoperative follow-up (mon) 53.25 ± 40.39
Combined surgery
Anti-VEGF 28 (56.0)
Anti-VEGF + gas tamponade + tPA 3 (6.0)
Gas tamponade 2 (4.0)
Oil tamponade 5 (10.0)
Oil tamponade + tPA 1 (2.0)
Oil tamponade + submacular hemorrhage drainage 1 (2.0)
Cataract surgery 42 (84.0)
Values are presented as mean ± standard deviation or number (%).
logMAR = logarithm of the minimal angle of resolution; AMD = age-related macular degeneration; PCV = polypoidal choroidal vascu-
lopathy; RAP = retinal angiomatous proliferation; VEGF = vascular endothelial growth factor; tPA = tissue plasminogen activator.
*Finger counting = 2.00 logMAR, hand motion = 2.30 logMAR, light perception = 2.60 logMAR, no light perception = 2.90.
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central foveal thickness (CFT), the presence of subretinal 
hemorrhages, and the appearance of subfoveal disciform 
scars at preoperation and at 1 and 24 months after the op-
eration. We defined CFT as the distance between the inter-
nal limiting membrane and Brunch’s membrane at the fo-
vea center and measured it by using the tool provided in 
the OCT software. 
Data were analyzed using IBM SPSS Statistics ver. 21.0 
(IBM Corp., Armonk, NY, USA). Variables including VA 
and injection parameters between groups were compared 
using two-sample paired t-tests. Logistic binary regression 
analysis was used to determine the predictive factors for 
visual outcomes. A p-value of <0.05 was considered to be 
statistically significant.
Results 
Fifty eyes from 50 patients who met the inclusion crite-
ria from a review of 382 patients were included; of these, 
23 (46%) were diagnosed with PCV and 27 (54%) were di-
agnosed with neovascular AMD, including one patient 
who had retinal angiomatous proliferation. The baseline 
characteristics are summarized in Table 1. The mean age 
was 71 years (range, 52–83 years), with no definite predi-
lection for either sex. The mean initial VA was 20 / 873 
(logMAR, 1.64 ± 0.73). Breakthrough vitreous hemorrhage 
was present at the first visit in 24 patients. In the remain-
ing 26 patients, mean VA before the onset of vitreous hem-
orrhage was 20/408 (logMAR, 1.31 ± 0.71). Preoperative 
VA measured at the time of vitreous hemorrhage was 
20/3027 (logMAR, 2.18 ± 0.34). The mean duration of fol-
low-up after surgery was 53.3 months (median, 36 months; 
range, 12–169 months), while the mean preoperative fol-
low-up period was 12.3 months (median, 3 months; range, 
0–104 months). Combined cataract surgery was performed 
in 42 eyes (84%). Silicone oil tamponade was performed in 
seven eyes, while gas tamponade was performed in five 
eyes (including four eyes with C3F8 and one with SF6). In-
travitreal tPA was deployed in four eyes (8%) and intravit-
real anti-VEGF was administered in 31 eyes (62%) during 
surgery. The injection interval prior to surgery was 3.31 ± 
3.92 months (median, 1.71 months; range, 0–17.16 months), 
whereas the postoperative injection interval frequency was 
17.24 ± 30.54 months (median, 6.50 months; range, 1.54–
159.00 months).
Best-corrected VA 
VA improved significantly after vitrectomy (Fig. 1). The 
overall mean postoperative best-corrected VA (BCVA) im-
proved from 20 / 3,027 (logMAR, 2.18 ± 0.34) to 20 / 873 
(logMAR, 1.64 ± 0.76; p < 0.001) at 12 months, and to 20 / 
853 (logMAR, 1.63 ± 0.75; p < 0.001) at 24 months. The 
improvement was further maintained until 36 months after 
surgery (n = 24, p < 0.001).
Next, we compared changes in VA based on eAMD sub-
type, i.e., PCV (n = 23) versus neovascular AMD (n = 27). 
Preoperative VA was not different between the PCV and 
neovascular AMD groups (20 / 2,700 vs. 20 / 3,400, re-
spectively; p = 0.353). While vision at the first postopera-
tive year demonstrated a significant difference between 
the subtypes (PCV 20 / 480 vs. neovascular AMD 20 / 
1,448; p = 0.025), the difference was no longer statistically 
significant at 2 years (PCV 20 / 563 vs. neovascular AMD 






































Fig. 1. Displaying preoperative visual acuity (VA) and postoper-
ative VA at 1, 6, and 12 months and 2 years after vitrectomy. Re-
sults represent the best-corrected visual acuity (BCVA) converted 
to logarithm of the minimum angle of resolution (logMAR). 
BCVA improvement at different postoperative time points was 
compared with the baseline preoperative VA and were all statisti-
cally significant (p < 0.001, two-sample paired t-tests). Polypoidal 
choroidal vasculopathy (PCV) and neovascular age-related mac-
ular degeneration (AMD) showed significant BCVA difference at 
1 year after vitrectomy only (*p < 0.05). POD = postoperative day.
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Anti-VEGF injections
Changes to the pattern of intravitreal anti-VEGF treat-
ment before and after vitrectomy were analyzed in 11 pa-
tients with clinical data prior to surgery. The mean preop-
erative follow-up and postoperative follow-up periods were 
36.82 months and 49.09 months, respectively. The mean 
injection interval prior to vitrectomy was 4.53 months (me-
dian, 3.53 months; range, 1.07–11.15 months); after vitrecto-
my, the injection interval significantly increased to 27.64 
months (median, 10.03 months; range, 1.05–64.14 months; 
p = 0.028). Further, the mean number of intravitreal an-
ti-VEGF injections decreased from 8.64 ± 4.99 injections 
(median, 7 injections) before surgery to 2.64 ± 2.87 (medi-
an, 2 injections) after surgery in a manner that was also 
significant (p < 0.001). 
OCT features
OCT features are summarized in Table 2. Preoperative-
ly, the CFT in 21 patients with OCT imaging was 699.8 ± 
356.7 μm, with 11 found to exhibit greater than 1,200 μm 
of CFT due to submacular hemorrhage. At 1 month after 
surgery, the thickness was reduced to 432.1 ± 282.0 μm, 
while, at 2 years, it was reduced further to 408.9 ± 271.6 
μm. When assessing CFT values at 24 months after sur-
gery, there were significant changes as compared with both 
preoperation (p = 0.036) and 1-month postoperation (p = 
0.038). However, the CFT at 1-month postoperation was 
not significantly reduced relative to that recorded preoper-
atively (p = 0.067). Additionally, the presence of subretinal 
hemorrhages was significantly reduced at 2 years after 
surgery when compared with just 1 month after surgery (p 
= 0.001) and before surgery (p < 0.001). Subfoveal disci-
form scarring was detected in 76.9% of patients by 2 years 
postoperation.
Predictive factors for long-term visual outcomes
Predictive factors for a 2-year favorable VA are summa-
rized in Table 3. Univariate analysis revealed that older age 
(odds ratio [OR], 0.879; p = 0.007) and the presence of sub-
macular hemorrhage (OR, 0.081; p = 0.022) were factors 
associated with a poor 2-year visual outcome. Subgroup 
analysis revealed that neovascular AMD showed worse vi-
sual prognosis at long-term follow-up relative to in the 
PCV group, although this was not statistically significant 
(OR, 0.344; p = 0.078). The trend of worse visual improve-
ment for neovascular AMD as compared with PCV can be 
appreciated visually in Fig. 1.
For surgical factors, combined cataract surgery (p = 
0.518) and adjuvant intravitreal anti-VEGF injection (p = 
0.518) demonstrated no significant effect on the visual 
prognosis. The use of several different tamponades, espe-
cially for eyes with submacular hemorrhage, was also as-
sessed, including gas (p = 0.124), silicone oil (p = 0.773), 
and tPA (p = 0.418), with all showing no correlation with 
the long-term visual outcome.
Multivariable analysis indicated that older age (OR, 
0.876; p = 0.026) and neovascular AMD (as compared with 
PCV) (OR, 0.137; p = 0.014) were significant negative fac-
tors influencing the 2-year visual outcome (Table 3).
Discussion
In our study, we reported the long-term results of vitrec-
tomy in patients with breakthrough vitreous hemorrhage 








preoperative vs. postoperative 24 mon 
// postoperative 1 mon vs. 24 mon
CFT (μm) 699.8 ± 356.7 432.1 ± 282.0 408.9 ± 271.6 0.036* // 0.038*
Subretinal hemorrhage 21 (100) 29 (82.9) 16 (41.0) <0.001*// 0.001*
Subfoveal disciform scarring - 14 (40.0) 30 (76.9) NA // <0.001*
Values are presented as mean ± standard deviation or number (%); Two-sample paired t-test and McNemar’s test.
CFT = central foveal thickness; NA = not applicable.
*p < 0.05.
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caused by eAMD and identified important prognostic fac-
tors inf luencing the final visual outcome. VA improved 
significantly and was maintained even at 2 years after sur-
gery. We also found that older age and neovascular AMD 
type as opposed to PCV type were associated with poorer 
2-year visual outcomes. 
Previous studies have reported sustained improvement 
after vitrectomy for eAMD with vitreous hemorrhage. 
Hasegawa et al. [11] discussed the effectiveness of surgical 
intervention in a case series with 31 patients followed up 
with for an average of 19.9 ± 14.2 months. Similar to in our 
study, these authors also observed that the VA recovered to 
a level similar to the vision at diagnosis or prior to the ap-
pearance of vitreous hemorrhage. Our results additionally 
showed that the 1-month postoperation BCVA stayed quite 
stable up until 2 years afterward, suggesting that the final 
visual outcome may be predicted with some accuracy as 
early as 1 month after surgery. However, in the aforemen-
tioned study, unlike in this present study, no significant 
prognostic factors were identified.
The normal aging process involves many vascular 
changes to the retina and choroid, leading to reduced cho-
roidal thickness and reduced choroidal flow and perfusion 
together with structural changes, such as a senescence of 
the retinal pigment epithelium cells and thickening of 
Bruch’s membrane from the accumulation of waste prod-
ucts and drusen [12,13]. These changes, in addition to ge-
netic predisposition and environmental stressors, may be 
implicated in the pathogenesis of eAMD [14]. Our study 
also found that age was a strong prognostic factor for pre-
dicting surgical outcomes, suggesting that this may be a 
consequence of age-related retinal degeneration and the 
Table 3. Regression analysis of prognostic factors associated with favorable postoperative 2-year visual acuity
Factor
Univariate Multiple*
OR (95% CI) p-value OR (95% CI) p-value
Age 0.879 (0.801–0.965) 0.007* 0.876 (0.780–0.984) 0.026*
Sex 1.745 (0.560–5.443) 0.56 - -
Diabetes 1.810 (0.396–8.261) 0.44 - -
Hypertension 1.806 (0.578–5.643) 0.309 - -
Preoperative visual acuity 0.215 (0.021–2.251) 0.20 - -
Presence of massive submacular hemorrhage 0.081 (0.009–0.697) 0.022* 0.118 (0.011–1.271) 0.078
Wet AMD type
PCV          Reference - - -
Neo-vascular AMD    0.344 (0.105–1.128) 0.078 0.137 (0.028–0.665) 0.014*
Tamponade type 
Gas (SF6 or C3F8) 6.182 (0.608–62.83) 0.124 - -
Silicone oil 0.773 (0.12–4.96) 0.773 - -
Combined cataract surgery 2.60 (0.220–30.745) 0.448 - -
Intravitreal tPA 0.418 (0.25–27.19) 0.418 - -
Intravitreal anti-VEGF 2.00 (0.629–6.361) 0.240 - -
Favorable visual acuity: better than finger count >0.01; Univariate and multivariate binary logistic regression analysis—only factors 
thought to be associated with favorable postoperative visual acuity in univariate analysis were included in the multivariate logistic regres-
sion model; Each tamponade was compared with the reference value of no tamponade for regression analysis. 
OR = odds ratio; CI = confidence interval; AMD = age-related macular degeneration; PCV = polypoidal choroidal vasculopathy; tPA = 
tissue plasminogen activator; VEGF = vascular endothelial growth factor.
*Statistically significant value (p-value <0.05).
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reduced ability to recover to a previous state.
In our study, we found that the presence of massive sub-
macular hemorrhage, defined as greater than 4-disc diam-
eters in the greatest linear length, was a significant nega-
tive factor (OR, 0.081; p = 0.02) for predicting favorable 
long-term visual outcomes during univariable regression 
analysis. This is in line with the established literature: 
Chang et al. [15] reported that eyes with submacular hem-
orrhages had worse BCVA outcomes at six months of fol-
low-up, while Cho et al. [16] observed that eyes with PCV 
developing massive submacular hemorrhages appeared to 
experience severe vision loss. Thus, the possibility of a 
massive submacular hemorrhage should be taken into ac-
count when performing vitrectomy and patient expecta-
tions should be moderated in light of the possibility of a 
poor visual outcome. Retinal toxicity from the iron con-
tained in degenerating red blood cells and hypoxic damage 
from reduced nutrient flux may induce long-term postop-
erative changes including retinal fibrosis and disciform 
scarring, reducing the final vision [17].
We additionally assessed the impact of adjuvant surgical 
techniques during vitrectomy, including combining cata-
ract surgery and various combinations of tamponade and 
intravitreal injections. In terms of combining cataract sur-
gery, previously published studies suggest conflicting re-
sults: Roufail et al. [5] observed in five surgeries that com-
bining cataract surgery for the treatment of AMD with 
breakthrough hemorrhage resulted in poor final outcomes; 
Chaudhry et al. [18], on the other hand, noted from among 
six surgeries that combining phacoemulsification appeared 
to be beneficial to the visual outcome. In our study, com-
bined cataract surgery was not associated with the final vi-
sual outcome (OR, 1.45; p = 0.518). A subset analysis of the 
42 cases with combined cataract surgery in our series 
found statistically significant vision improvements from 
preoperative vision (p = 0.003). Finally, the choice of tam-
ponade, whether gas, silicone oil, or no tamponade, was 
not found to be an influential factor predicting the final vi-
sual outcome.
Numerous studies, including the pivotal ANCHOR and 
MARINA trials, have emphasized the effectiveness of in-
travitreal anti-VEGF therapy in eAMD patients [19,20]. In 
our study, we observed that the average time interval be-
tween injections significantly increased after vitrectomy to 
more than 20 months after surgery. This resulted in the re-
duction of the average number of injections per patient 
performed after vitrectomy. The prolonged stabilization 
and reduced disease activity after vitrectomy noted in this 
study may be the result of increased oxygenation satura-
tion in vitrectomized eyes [21] and reduced the oxygen 
need as a result of retinal atrophy and reduced metabolic 
activity. In fact, Baek et al. [22] observed similarly dimin-
ished disease activity in PCV eyes after the occurrence of 
submacular hemorrhage and postulated that the reduced 
number of polyps seen following hemorrhage occurrence 
may be the primary cause. Their study showed that, in 52 
PCV eyes, at least one polypoidal lesion disappeared after 
hemorrhage in seven of 10 eyes (70%) and the injection 
frequency diminished after hemorrhage as compared with 
in control eyes, which were PCV eyes without hemorrhage 
(p < 0.001) [22].
Finally, in line with the current literature [23], we also 
observed that PCV eyes had relatively more favorable vi-
sual outcomes than did neovascular AMD eyes. We com-
pared the VA between the two subtypes of eAMD and a 
significant difference was noted in vision at 1-year postop-
eration. However, further analysis did reveal that this dif-
ference appeared to lose statistical significance by the sec-
ond year. Further long-term studies might reveal the 
ultimate prognosis of eAMD patients depending on these 
subtypes.
This was a retrospective study with limitations inherent 
to its design, without control of the baseline characteristics 
and heterogeneity of the data in terms of adjuvant surgical 
techniques. Also, vitrectomy was performed by several 
different surgeons. We were able to find an association be-
tween surgical treatment and decreasing anti-VEGF treat-
ment intervals/numbers; however, further clinical studies 
focusing on anti-VEGF and vitrectomy are required to es-
tablish the possibility of a causal relationship. The 
strengths of our study are that we included a relatively 
large number of patients with long-term follow-up and our 
findings encompassed results from both PCV and neovas-
cular AMD eyes. Future carefully designed prospective 
studies will help to elucidate the optimal combination of 
adjuvant techniques to achieve the best visual outcomes.
In conclusion, we report the long-term visual outcomes 
and possible prognostic factors for patients with vitreous 
hemorrhage associated with eAMD undergoing surgical 
intervention. Age at onset and differentiating PCV with 
typical neovascular AMD appear to be important prognos-
tic factors predicting the long-term visual outcomes. Alto-
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gether, vitrectomy resulted in visual improvement. Break-
through vitreous hemorrhage in eAMD appears to be 
associated with a decreased need for anti-VEGF therapy.
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